Terms: = Lung cancer AND HIP1, ILWEQ, 3092, ENSG00000127946
23 results:
1. Therapeutic Advances of Rare ALK Fusions in Non-Small Cell lung cancer.
Xiang Y; Zhang S; Fang X; Jiang Y; Fang T; Liu J; Lu K
Curr Oncol; 2022 Oct; 29(10):7816-7831. PubMed ID: 36290895
[TBL] [Abstract] [Full Text] [Related]
2. Identification of triple gene fusion ALK-LRRN2, LTBP1-ALK, and hip1-ALK in advanced lung adenocarcinoma and response to alectinib: A case report.
Ning S; Shi C; Zhang H; Li J
Medicine (Baltimore); 2021 Dec; 100(51):e27999. PubMed ID: 34941039
[TBL] [Abstract] [Full Text] [Related]
3. Effectiveness of Postoperative or Preoperative Radiotherapy on Prognosis in Patients with Stage II Resectable Non-Small Cell lung cancer: A Retrospective Study Based on the SEER Database.
Chen D; Yu J
Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833420
[No Abstract] [Full Text] [Related]
4. Clinicopathological features and resistance mechanisms in hip1-ALK-rearranged lung cancer: A multicenter study.
Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ
Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488
[TBL] [Abstract] [Full Text] [Related]
5. Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy.
Wang CY; Sheng CC; Ma GL; Xu D; Liu XQ; Wang YY; Zhang L; Cui CL; Xu BH; Song YQ; Zhu J; Jiao Z
Acta Pharmacol Sin; 2021 Aug; 42(8):1368-1375. PubMed ID: 33154554
[TBL] [Abstract] [Full Text] [Related]
6. Unique molecular features and clinical outcomes in young patients with non-small cell lung cancer harboring ALK fusion genes.
Tian P; Liu Y; Zeng H; Tang Y; Lizaso A; Ye J; Shao L; Li Y
J Cancer Res Clin Oncol; 2020 Apr; 146(4):935-944. PubMed ID: 31894386
[TBL] [Abstract] [Full Text] [Related]
7. [Risk factors analysis for one-year and long-term mortality in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease].
Zhang Y; Lin YX
Zhonghua Jie He He Hu Xi Za Zhi; 2019 Dec; 42(12):895-900. PubMed ID: 31826532
[No Abstract] [Full Text] [Related]
8. [The characteristics of lung adenocarcinoma driver gene variants detected by high-throughput sequencing and quantitative fluorescence PCR].
Chen LF; Chen XY; Lin J; Yu XB; Jin L
Zhonghua Bing Li Xue Za Zhi; 2019 Oct; 48(10):772-778. PubMed ID: 31594041
[No Abstract] [Full Text] [Related]
9. Analysis of the Genomic Landscape in ALK+ NSCLC Patients Identifies Novel Aberrations Associated with Clinical Outcomes.
Couëtoux du Tertre M; Marques M; Tremblay L; Bouchard N; Diaconescu R; Blais N; Couture C; Pelsser V; Wang H; Higenell V; Izzi L; Gambaro K; Hoffert C; Srivastava A; Spatz A; Rousseau C; McNamara S; Cohen V; Batist G; Agulnik J
Mol Cancer Ther; 2019 Sep; 18(9):1628-1636. PubMed ID: 31243098
[TBL] [Abstract] [Full Text] [Related]
10. Thoracic Oncology Multidisciplinary Clinic Reduces Unnecessary Health Care Expenditure Used in the Workup of Patients With Non-small-cell lung cancer.
Voong KR; Liang OS; Dugan P; Torto D; Padula WV; Senter JP; Lang M; Hooker CM; Feliciano J; Broderick S; Yarmus L; Khanna K; Narang A; Hales RK
Clin Lung Cancer; 2019 Jul; 20(4):e430-e441. PubMed ID: 30956040
[TBL] [Abstract] [Full Text] [Related]
11. Circular RNA expression profiles and features in human tissues: a study using RNA-seq data.
Xu T; Wu J; Han P; Zhao Z; Song X
BMC Genomics; 2017 Oct; 18(Suppl 6):680. PubMed ID: 28984197
[TBL] [Abstract] [Full Text] [Related]
12. Custom Gene Capture and Next-Generation Sequencing to Resolve Discordant ALK Status by FISH and IHC in lung Adenocarcinoma.
Jang JS; Wang X; Vedell PT; Wen J; Zhang J; Ellison DW; Evans JM; Johnson SH; Yang P; Sukov WR; Oliveira AM; Vasmatzis G; Sun Z; Jen J; Yi ES
J Thorac Oncol; 2016 Nov; 11(11):1891-1900. PubMed ID: 27343444
[TBL] [Abstract] [Full Text] [Related]
13. Huntingtin-Interacting Protein-1 Is an Early-Stage Prognostic Biomarker of lung Adenocarcinoma and Suppresses Metastasis via Akt-mediated Epithelial-Mesenchymal Transition.
Hsu CY; Lin CH; Jan YH; Su CY; Yao YC; Cheng HC; Hsu TI; Wang PS; Su WP; Yang CJ; Huang MS; Calkins MJ; Hsiao M; Lu PJ
Am J Respir Crit Care Med; 2016 Apr; 193(8):869-80. PubMed ID: 26595459
[TBL] [Abstract] [Full Text] [Related]
14. Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches.
Drilon A; Wang L; Arcila ME; Balasubramanian S; Greenbowe JR; Ross JS; Stephens P; Lipson D; Miller VA; Kris MG; Ladanyi M; Rizvi NA
Clin Cancer Res; 2015 Aug; 21(16):3631-9. PubMed ID: 25567908
[TBL] [Abstract] [Full Text] [Related]
15. Identification of a novel hip1-ALK fusion variant in Non-Small-Cell lung cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
[TBL] [Abstract] [Full Text] [Related]
16. A novel fusion of TPR and ALK in lung adenocarcinoma.
Choi YL; Lira ME; Hong M; Kim RN; Choi SJ; Song JY; Pandy K; Mann DL; Stahl JA; Peckham HE; Zheng Z; Han J; Mao M; Kim J
J Thorac Oncol; 2014 Apr; 9(4):563-6. PubMed ID: 24736082
[TBL] [Abstract] [Full Text] [Related]
17. hip1-ALK, a novel fusion protein identified in lung adenocarcinoma.
Hong M; Kim RN; Song JY; Choi SJ; Oh E; Lira ME; Mao M; Takeuchi K; Han J; Kim J; Choi YL
J Thorac Oncol; 2014 Mar; 9(3):419-22. PubMed ID: 24518094
[TBL] [Abstract] [Full Text] [Related]
18. hip1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract] [Full Text] [Related]
19. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.
Cuzick J; Sestak I; Baum M; Buzdar A; Howell A; Dowsett M; Forbes JF;
Lancet Oncol; 2010 Dec; 11(12):1135-41. PubMed ID: 21087898
[TBL] [Abstract] [Full Text] [Related]
20. [Burden of major cancers on years of life lost with premature death in crocidolite-contaminated area in Dayao].
Zou H; Luo SQ; Yang CY; Zhang MB
Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi; 2007 Jun; 25(6):326-30. PubMed ID: 17723186
[TBL] [Abstract] [Full Text] [Related]
[Next]
